A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Exclusion Criteria Concurrent Medication: Excluded: * Terfenadine, astemizole, cisapride, triazolam, or midazolam (competition for the enzyme cytochrome P-450 3A4 \[CYP3A4\] by indinavir could result in inhibition of metabolic breakdown of these drugs and create the potential for serious and/or life threatening events \[i.e., cardiac arrhythmia, prolonged sedation\]). * Rifampin or rifabutin (prohibited because of potential drug interaction with indinavir). * Ketoconazole, itraconazole, and clarithromycin. * Concomitant systemic therapy for acute opportunistic infection or malignancy. Excluded: Life expectancy less than 12 months. Prior Medication: Excluded: * Prior treatment with efavirenz, 3TC, an NNRTI, or an HIV protease inhibitor. * Prior antiretroviral agent within 14 days of initiating study treatment. * Prior treatment (within 30 days of initiating study treatment) with any other experimental drug for any indication. Patients must: * Have a diagnosis of HIV infection. * Have CD4 counts greater than or equal to 50 cell/mm3. * Have a life expectancy greater than or equal to 12 months. * Be post-pubescent.